慢阻肺中度或重度恶化定义为门诊或住院慢阻肺患者处方口服糖皮质激素。 研究显示,接受SGLT2抑制剂(9.26/100人年 vs. 11.4/100人年;HR=0.81, 95%CI:0.76~0.86)或GLP-1受体激动剂治疗的患者(9.89/100人年 vs. 11.49/100人年;HR...
28 SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ. 2024 Jun 26;385:e078483. doi...
Pooled results showed no significant difference in the incidence of MACE between diabetic medications (GLP-1RA, SGLT-2i, or DPP-4i) and placebo in black patients with type 2 diabetes (RR[95%CI] = 0.94 [0.77,1.16]). On restricting the analysis to different diabetic medication classes, ...
5.Miller A, Joyce B, Bartelt K, Deckert J. Most GLP-1 Medications Correlated with a Lower Likelihood of Anxiety and Depression Diagnoses. Epic Research. https://epicresearch.org/articles/most-glp-1-medications-correlated-with-a-lower-likelihood-of-anxiety-and-depression-diagnoses. Accessed on ...
SGLT-2抑制剂和GLP-1受体激动剂的联合使用_替代终点和硬终点的潜在好处.pdf,1879 Send Orders for Reprints to reprints@benthamscience.ae Current Pharmaceutical Design, 2018, 24, 1879-1886 REVIEW ARTICLE Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agoni
16. Harris ST, Patorno E, Zhuo M, Kim SC, Paik JM. Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study. Diabetes Care 2021;44:2293-301. 10.2337/dc21-0529 17. Rossing P, Caramori ML, Chan JCN, et al.. Executive...
These medications exert o w Clinical decisions about treatment of type 2 diabetes different effects on stroke, hospitalisations for heart n l o a have been led by glycaemic control for decades. failure, and key adverse events in different d SGLT-2 inhibitors and GLP-1 receptor agonists are ...
凯斯西储大学医学院Rong Xu教授团队通过分析超过100万名2型糖尿病患者的三年医疗电子记录发现,使用司美格鲁肽的患者相较于使用其他降糖药物(包括胰岛素、二甲双胍、DDP-4i、SGLT2i、磺酰脲类药物、噻唑烷二酮及其他GLP-1R类药物)的患者,首次诊断为阿尔茨海默病的风险显著降低——与胰岛素使用者相比降低67%,与...
1). Both groups exhibited insignificant differences in age, sex, race, comorbidities, medications, and most lab results. The mean eGFRs in the GLP-1 RAs users and non-users groups were 73.2 and 75.9 ml/min/1.73 m2, respectively. Throughout the follow-up period, HbA1C levels remained ...
凯斯西储大学医学院Rong Xu教授团队通过分析超过100万名2型糖尿病患者的三年医疗电子记录发现,使用司美格鲁肽的患者相较于使用其他降糖药物(包括胰岛素、二甲双胍、DDP-4i、SGLT2i、磺酰脲类药物、噻唑烷二酮及其他GLP-1R类药物)的患者,首次诊断为阿尔茨海默病的风险显著降低——与胰岛素使用者相比降低67%,与...